Abstract. Tau abnormal hyperphosphorylation and the formation of neurofibrillary tangles in the Alzheimer's disease (AD) brain is the result of upregulation of tau kinases. In a group of 729 Spanish late-onset AD patients and 670 healthy controls, we examined variations into a set of 20 candidate genes of kinases involved in tau phosphorylation at AD-related sites (PRKACB; CAMK2A; MARK1, 2, 3 and 4; CSNK1D; CDC2; RPS6KB1 and 2; p38␣ and ␤; IB1; JNK1, 2 and 3; MEK1 and 2; ERK1 and 2), to address hypotheses of genetic variation that might influence both AD risk and age at disease onset. There was an increased frequency of RPS6KB2 (intron 2, rs917570) minor allele in patients (50%) versus controls (39%) (OR = 1.52; 95% CI 1.30-1.77; p = 1.24 × 10 −5 Bonferroni corrected), and the presence of this minor allele was significantly (p = 4.2 × 10 −5 ) associated with a 3-years later onset of AD (mean age 74.1 years) when compared to age at onset of non-minor allele carriers (mean age 71.1 years). In APOE non-4 allele carriers, the combined effect of AD-associated risk alleles from the genes of CDC2, RPS6KB1 and 2, p38␣, JNK (1, 2 and 3), MEK2, and ERK2 was significantly (p = 0.002) associated with a late-onset (>76 years) of AD. The CDC2 AGC haplotype derived from SNPs in introns 3 (rs2448347), 5 (rs2456772), and 7 (rs1871447) showed a protective effect against AD in APOE non-4 allele carriers (permutation p = 1.0 × 10 −4 ) with a frequency of 9% in cases and 15% in controls. Common genetic variation in the tau kinases pathway does underlie individual differences not only in susceptibility to AD but also in disease phenotype (age at disease onset).
INTRODUCTION
One of the neuropathological hallmarks in Alzheimer's disease (AD) is neurofibrillary tangles (NFTs), which are composed of the microtubulebinding protein tau that is hyperphosphorylated [1] [2] [3] .
Tau abnormal hyperphosphorylation is the result of upregulation of tau kinases, and GSK3-␤ and CDK5 are among the kinases most implicated in the abnormal hyperphosphorylation of tau in AD brains [3] . The inhibition of abnormal hyperphosphorylation of tau is one of the most promising therapeutic targets for the development of disease modifying drugs, and it has been suggested that inhibition of either both GSK3-␤ and CDK5 or one of these two kinases plus PRKA or CAMK2 might be required to inhibit AD neurofibrillary degeneration [4] . All this data postulates a role for tau kinases as interesting genetic targets for association analysis of AD. We have previously examined the contribution of some tau kinases genes such as GSK3-␤ [5] , CDK5 [6] , CDK5R1 [7] , DYRK1A [8] , and TTBK1 [9] to the susceptibility to AD. In the present study, we extended previous investigations by evaluating variations into an exhaustive list of all known genes of kinases involved in tau phosphorylation at AD-related sites, in relation to both AD risk and age at disease onset, in a Spanish cohort.
METHODS

Subjects
The study included 729 AD patients (67% women; mean age at study 77.2 years; SD 8.0; range 61-103 years; mean age at onset 73.3 years; SD 7.8; range 60-100 years) who met NINCDS/ADRDA criteria for probable AD [10] . All AD cases were defined as sporadic because their family history did not mention any first-degree relative with dementia. AD patients were recruited from the Departments of Neurology of University Hospital "Marqués de Valdecilla" (Santander, Spain) and Hospital "La Paz" (Madrid, Spain), and from Alzheimer Center Reina Sofia Foundation (Madrid, Spain). The large majority of patients was living in the community and had been referred by their general practitioner; few had been admitted from hospital wards or nursing home facilities. Control subjects were 670 unrelated individuals (64% women; mean age 78.3 years; SD 9.4; range 60-104 years) randomly selected from nursing homes. These subjects had complete neurologic and medical examinations that showed that they were free of significant illness and had Mini Mental State Examination scores of 28 or more, which were verified by at least one subsequent annual following-up assessment. The controls arose from the same base population as the cases. The AD and control samples were Caucasians originating from a limited geographical area in northern Spain (Santander) and from the central area of Spain (Madrid).
Genotyping
Blood samples were taken after written informed consent had been obtained from the subjects or their representatives. The study was approved by the ethical committees of the University Hospital "Marqués de Valdecilla", Alzheimer Center Reina Sofia Foundation, and the Hospital "La Paz". Genotyping of cAMP-dependent kinase A catalytic subunit ␤ (PRKACB), calmodulin-dependent protein kinase-II ␣ (CAMK2A), microtubule-affinity regulating kinases (MARK1, 2, 3 and 4), casein kinase-1 δ (CSNK1D), cell division cycle 2 kinase (CDC2), ribosomal S6 protein kinases (RPS6KB1 and 2), p38␣ and ␤, isletbrain 1/C-Jun N-terminal kinase interacting protein 1 (IB1), C-Jun N-terminal kinases (JNK1, 2 and 3), MEK1 and 2, and extracellular signal-regulated kinases (ERK1 and 2) was performed using the iPLEX Gold assay on the MassArray system (Sequenom Inc., San Diego, USA). We used data from the HapMap project (http://www.hapmap.org) to select htSNPs capturing 92% of PRKACB genetic variability, 91% of CAMK2A, 91% of MARK1, 90% of MARK2, 89% of MARK3, 91% of MARK4, 100% of CSNK1D, 90% of CDC2, 93% of RPS6KB1, 100% of RPS6KB2, 91% of p38␣, 100% of p38␤, 100% of IB1, 92% of JNK1, 88% of JNK2, 87% of JNK3, 80% of MEK1, 90% of MEK2, 100% of ERK1, and 93% of ERK2 genetic variability in Caucasians. SNPs were chosen among those with minor allele frequencies ≥5% using Haploview v3.2 software (http://www.broad.mit.edu/mpg/haploview) with an r 2 threshold of 0.8.
Statistical analysis
Hardy-Weinberg equilibrium (HWE) was calculated for the htSNPs in the control population using Pearson's χ 2 statistics. We assessed pairwise linkage disequilibrium (LD) between the htSNPs by D' and r 2 statistics. Haplotype reconstruction and their frequencies in cases and controls were estimated by an expectation-maximization algorithm, method implemented in Haploview 3.32. Pearson's χ 2 statistics were performed to compare allele and haplotype distribution of the patients and control for each htSNP. Allelic distributions were assessed by logistic regression using the package SPSS 13.0 for Windows (SPSS, Inc, Chicago, Illinois). In order to obtain a measure of significance corrected for multiple testing, we used Bonferroni's method to correct our nominal p-values for all 85 tests performed, corresponding to the 85 SNPs analyzed. In our haplotype analysis we chose a less conservative approach, permutation test, to adjust for multiple testing. By using Student's t test and stratifying by APOE 4 allele status, we tested for differences in age at disease onset depending on allele distributions of the AD-associated risk SNPs. In addition, we calculated for each subject a cumulative genetic risk score (GRS) defined as the number of nominally significant (p < 0.05) AD-associated risk alleles from our list of tau kinases pathway genes, and we correlated the GRS with age at AD onset using Pearson's r 2 ; moreover, we compared by ANOVA test the GRS distributions across patient's age at disease onset divided into quintiles.
RESULTS
PRKACB rs7515976 and rs11163911, CAMK2A rs6881743, MARK2 rs11231637, MARK4 rs344807, CSNK1D rs12601586, CDC2 rs3213058, RPS6KB1 rs180523, p38␤ rs742186, JNK2 rs6868333, MEK2 rs350896 and ERK1 rs11865086 SNPs were significantly deviated from HWE, and therefore, they were excluded from the analysis; these deviations could be the result of a genotyping error. As shown in Table 1 , the distribution of the minor allele frequencies of the tau kinases genes did not differ significantly between AD and control groups, except for RPS6KB2 (intron 2, rs917570) minor allele that was increased in patients (50%) versus controls (39%) (OR = 1.52; 95% CI 1.30-1.77; p = 1.24 × 10 −5 Bonferroni corrected). Haplotype distributions were not significantly different between cases and controls in the overall analysis or after stratification by APOE 4 allele, except for CDC2 gene (Table 2) : the AGC haplotype derived from SNPs in introns 3 (rs2448347), 5 (rs2456772), and 7 (rs1871447) showed a protective effect against AD only in APOE 4 allele noncarriers (permutation p = 1.0 × 10 −4 ), with a frequency of 9% in cases and 15% in controls.
Age of AD onset was 3 years later (mean age 74.13, SD 7.51) in patients carrying RPS6KB2 (intron 2, rs917570) minor allele compared to non-minor allele carriers (mean age 71.16, SD 8.22; p = 4.2 × 10 −5 ), with this significant association being equally present in APOE 4 allele carriers (p = 0.006) and APOE non-4 allele carriers (p = 0.002). We selected 9 htSNPs (CDC2 rs1871447, RPS6KB1 rs8071475, RPS6KB2 rs917570, p38␣ rs851019, JNK1 rs10857565, JNK2 rs6601105, JNK3 rs4693136, MEK2 rs10250, and ERK2 rs1063311) with nominally significant (p < 0.05) AD association from the tau kinases pathway (Table 1) , and examined the simultaneous effect of all these AD-associated risk alleles (genetic risk score, GRS) on the age of AD onset. In APOE non-4 allele carriers, we found a statistically significant correlation (r 2 = 0.177; p = 0.001) between GRS and age at AD onset, and this correlation remained statistically significant after removing RPS6KB2 (intron 2, rs917570) from the analysis (r 2 = 0.118, p = 0.026); conversely, in APOE 4 allele carriers there was no correlation (r 2 = 0.75; p = 0.15) between GRS and age at onset. When age at AD onset was divided into quintiles ( Fig. 1) , GRS values increased significantly (p = 0.002) in late-onset (>76 years) patients, in the APOE non-4 allele carriers; in contrast, there were no statistically significant GRS differences (p = 0.49) between quintile groups in APOE 4 allele carriers.
DISCUSSION
The largest genome-wide association study (GWA) in AD [11] did not find significant results for genes directly related to tau phosphorylation. However, it cannot be discarded that these genes in the tau kinases pathway are among the genes with significant nominal association but without reaching significance (p < 5 × 10 −8 ) after adjustment for multiple testing in GWAs; in addition, it is also possible that some of the SNPs analyzed in our study were not present in the arrays used in GWAs or were lost during the strict quality control checks. Moreover, genes harboring markers with only modest evidence of association can be identified if they belong to the same biological pathway or mechanism; therefore, pathway-based approaches, which jointly consider multiple variants in interacting or related genes, might complement the most-significant SNPs/genes approach for interpreting GWA data on complex diseases [12, 13] . In fact, genetic variation in the immune system and in lipid metabolism pathways is a cause of AD susceptibility [14, 15] . Tau kinases genes can be divided into two major groups, i.e., the proline-directed tau kinases and non-proline-directed tau kinases (Fig. 2) . The nonproline-directed tau kinases genes CAMK2A, MARKs (1, 2, 3 and 4), and PRKACB, were not associated with the AD risk in our study. Tau-tubuline kinase 1 (TTBK1) is another non-proline-directed kinase and Haplotype block consists of SNPs rs2448347 (intron 3), rs2456772 (intron 5), and rs1871447 (intron 7). Rare haplotypes (total frequency < 0.05) were excluded from the analysis. * Multiple testing correction with 10,000 permutations. Fig. 1 . Box plot showing correlation between age at AD onset divided into quintiles on the x-axis and cumulative genetic risk score (GRS) on the y-axis, in APOE non-4 allele carriers. GRS is defined as the number of nominally significant (p < 0.05) AD-associated risk alleles from our list of tau kinases pathway genes (CDC2 rs1871447, RPS6KB1 rs8071475, RPS6KB2 rs917570, p38␣ rs851019, JNK1 rs10857565, JNK2 rs6601105, JNK3 rs4693136, MEK2 rs10250, and ERK2 rs1063311).
we recently [9] found that subjects carrying two copies of the minor allele of markers in introns 1, 5 and 9 had a reduced risk of AD; these findings have been replicated in Han Chinese [16] . The proline-directed tau kinases genes CSNK1D and the mitogen-activated protein kinase (MAPK) family comprising p38s (␣ and ␤), JNKs (1, 2 and 3) and its activator IB1, and ERKs (1 and 2) and their activators MEKs (1 and 2), were not associated with AD risk in the present study. However, the interaction between the minor allele of a polymorphism in the 5´regulatory region (−499, rs1554338) of IB1 and either the major allele of LRP1 (exon 3, rs1799986) [17] or the minor allele of LRP8 (exon 19, rs5174) [18] has been associated with AD risk.
We have shown in this study, for the first time, that the RPS6KB2 (intron 2, rs917570) minor allele was associated with increased AD risk and a later onset of AD, and that the combined effect of AD-associated risk alleles from the genes of CDC2, RPS6KB1 and 2, p38␣, JNK (1, 2 and 3), MEK2 and ERK2, was also associated with a later onset of AD, in APOE non-4 allele carriers. Late-onset AD patients might have a different genetic background compared with earlyonset AD patients that might enhance the effect of all these tau kinases pathway risk alleles, leading to a late expression of the disease. A polymorphism in the exon 6 (rs321239) of CDC2 was associated with AD risk in the Swedish population [19] , and a haplotype derived from SNPs in exon 6 (rs321239) and exon 7 (rs2456777 and rs2456778) increased the risk of AD in APOE 4 carriers from Sicily [20] , but a large study in Caucasian Americans failed to demonstrate this association [21] ; conversely, a haplotype derived from SNPs in introns 3 (rs2448347), 5 (rs2456772), and 7 (rs1871447) of CDC2 showed a protective effect against AD in APOE 4 allele noncarriers in our population. The concentration of both activated CDC2 [22] and RPS6KBs [23] increases in AD brain and their distribution coincide with the progression of neurofibrillary degeneration. Possible mechanisms that contribute to the association between CDC2 and RPS6KBs polymorphisms and the risk of AD are unknown, as information about the expression of these proline-directed kinases at the brain level in subjects with different genotypes is lacking.
NON PROLINE-DIRECTED TAU KINASES
The genes of the two major proline-directed kinases genes involved in the abnormal hyperphosphorylation of tau in AD, GSK3-␤ and CDK5, have been associated with AD risk: subjects carrying the functional haplotype conformed by the minor allele of GSK3-␤ (−50, rs344558) and the major allele of GSK3-␤ (−157, rs6438552), independently [24] or in combination with at least one copy of the microtubule-associated protein tau H2 haplotype [5, 25] , had an increase risk for AD. In a Dutch case-control series [26] , the CDK5 haplotype composed of 5´UTR (rs2069442), intron 5 (rs2069454), intron 9 (rs891507 and rs2069459) and 3´UTR (rs9278) was significantly associated with AD in non-carriers of the APOE 4 allele, but these findings were not confirmed in our Spanish population [6] ; however, we observed that a polymorphism in the 3´UTR region (rs735555) of the gene activator of CDK5 (CDK5R1) interacted with the major allele of GSK3-␤ (−50, rs344558) to decrease AD risk [7] . Finally, a haplotype with markers located from 30 kb upstream of exon 1 to exon 13 in the proline-directed tau kinase gene DYRK1A showed association with AD risk in the Japanese population [27] , but we did not replicate this genetic association [8] .
In the tau kinases pathway, our present negative results with the genes of PRKACB, CAMK2A, MARK (1, 2, 3 and 4), CSNK1D, p38␤, IB1, MEK1, and ERK1 are probably not due to insufficient statistical power, because our sample size had enough power (>82%) to detect and odds ratio of 1.3 at disease allele frequencies of 0.20. Conversely, our present positive findings suggest that CDC2 and RPS6KB2 are promising candidate tau phosphorylation-related genes for AD risk.
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